A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma

• Status: NOT_YET_RECRUITING
• Trial end date: 2028-05-01

Summary

The aim of this study is to evaluate the efficacy and safety of Glofitamab combined with Orelabrutinib and Bortezomib in patients with high-risk mantle cell lymphoma

• Phase: PHASE2

Details

• Lead Sponsor: Ruijin Hospital
• Treatments: Bortezomib; glofitamab; obinutuzumab; orelabrutinib